FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118730804> ?p ?o ?g. }

• W2118730804 endingPage "1148" @default.
• W2118730804 startingPage "1142" @default.
• W2118730804 abstract "ABSTRACT We investigated the activity of linezolid, alone and in combination with rifampin (rifampicin), against a methicillin-resistant Staphylococcus aureus (MRSA) strain in vitro and in a guinea pig model of foreign-body infection. The MIC, minimal bactericidal concentration (MBC) in logarithmic phase, and MBC in stationary growth phase were 2.5, >20, and >20 μg/ml, respectively, for linezolid; 0.01, 0.08, and 2.5 μg/ml, respectively, for rifampin; and 0.16, 0.63, >20 μg/ml, respectively, for levofloxacin. In time-kill studies, bacterial regrowth and the development of rifampin resistance were observed after 24 h with rifampin alone at 1× or 4× the MIC and were prevented by the addition of linezolid. After the administration of single intraperitoneal doses of 25, 50, and 75 mg/kg of body weight, linezolid peak concentrations of 6.8, 12.7, and 18.1 μg/ml, respectively, were achieved in sterile cage fluid at ≈3 h. The linezolid concentration remained above the MIC of the test organism for 12 h with all doses. Antimicrobial treatments of animals with cage implant infections were given twice daily for 4 days. Linezolid alone at 25, 50, and 75 mg/kg reduced the planktonic bacteria in cage fluid during treatment by 1.2 to 1.7 log 10 CFU/ml; only linezolid at 75 mg/kg prevented bacterial regrowth 5 days after the end of treatment. Linezolid used in combination with rifampin (12.5 mg/kg) was more effective than linezolid used as monotherapy, reducing the planktonic bacteria by ≥3 log 10 CFU ( P < 0.05). Efficacy in the eradication of cage-associated infection was achieved only when linezolid was combined with rifampin, with cure rates being between 50% and 60%, whereas the levofloxacin-rifampin combination demonstrated the highest cure rate (91%) against the strain tested. The linezolid-rifampin combination is a treatment option for implant-associated infections caused by quinolone-resistant MRSA." @default.
• W2118730804 created "2016-06-24" @default.
• W2118730804 creator A5027422217 @default.
• W2118730804 creator A5033005712 @default.
• W2118730804 creator A5068817061 @default.
• W2118730804 creator A5071531513 @default.
• W2118730804 creator A5080647333 @default.
• W2118730804 date "2009-03-01" @default.
• W2118730804 modified "2023-09-23" @default.
• W2118730804 title "Linezolid Alone or Combined with Rifampin against Methicillin-Resistant <i>Staphylococcus aureus</i> in Experimental Foreign-Body Infection" @default.
• W2118730804 cites W1756182513 @default.
• W2118730804 cites W1859276716 @default.
• W2118730804 cites W1963989503 @default.
• W2118730804 cites W1964911927 @default.
• W2118730804 cites W1973179753 @default.
• W2118730804 cites W1983255179 @default.
• W2118730804 cites W2010516143 @default.
• W2118730804 cites W2028526922 @default.
• W2118730804 cites W2043770077 @default.
• W2118730804 cites W2055460437 @default.
• W2118730804 cites W2070922113 @default.
• W2118730804 cites W2073791094 @default.
• W2118730804 cites W2077608176 @default.
• W2118730804 cites W2097548272 @default.
• W2118730804 cites W2100817487 @default.
• W2118730804 cites W2110498109 @default.
• W2118730804 cites W2117409056 @default.
• W2118730804 cites W2117961052 @default.
• W2118730804 cites W2121150640 @default.
• W2118730804 cites W2131727615 @default.
• W2118730804 cites W2132846513 @default.
• W2118730804 cites W2134137013 @default.
• W2118730804 cites W2137831211 @default.
• W2118730804 cites W2141649668 @default.
• W2118730804 cites W2145394576 @default.
• W2118730804 cites W2149375508 @default.
• W2118730804 cites W2149579827 @default.
• W2118730804 cites W2150324756 @default.
• W2118730804 cites W2153862539 @default.
• W2118730804 cites W2156217104 @default.
• W2118730804 cites W2156283731 @default.
• W2118730804 cites W2163970869 @default.
• W2118730804 cites W2164974110 @default.
• W2118730804 cites W2167093953 @default.
• W2118730804 cites W2168912597 @default.
• W2118730804 cites W72529186 @default.
• W2118730804 cites W87013843 @default.
• W2118730804 doi "https://doi.org/10.1128/aac.00775-08" @default.
• W2118730804 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2650529" @default.
• W2118730804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19075065" @default.
• W2118730804 hasPublicationYear "2009" @default.
• W2118730804 type Work @default.
• W2118730804 sameAs 2118730804 @default.
• W2118730804 citedByCount "106" @default.
• W2118730804 countsByYear W21187308042012 @default.
• W2118730804 countsByYear W21187308042013 @default.
• W2118730804 countsByYear W21187308042014 @default.
• W2118730804 countsByYear W21187308042015 @default.
• W2118730804 countsByYear W21187308042016 @default.
• W2118730804 countsByYear W21187308042017 @default.
• W2118730804 countsByYear W21187308042018 @default.
• W2118730804 countsByYear W21187308042019 @default.
• W2118730804 countsByYear W21187308042020 @default.
• W2118730804 countsByYear W21187308042021 @default.
• W2118730804 countsByYear W21187308042022 @default.
• W2118730804 countsByYear W21187308042023 @default.
• W2118730804 crossrefType "journal-article" @default.
• W2118730804 hasAuthorship W2118730804A5027422217 @default.
• W2118730804 hasAuthorship W2118730804A5033005712 @default.
• W2118730804 hasAuthorship W2118730804A5068817061 @default.
• W2118730804 hasAuthorship W2118730804A5071531513 @default.
• W2118730804 hasAuthorship W2118730804A5080647333 @default.
• W2118730804 hasBestOaLocation W21187308041 @default.
• W2118730804 hasConcept C176947019 @default.
• W2118730804 hasConcept C185592680 @default.
• W2118730804 hasConcept C26381139 @default.
• W2118730804 hasConcept C2777052132 @default.
• W2118730804 hasConcept C2778607973 @default.
• W2118730804 hasConcept C2778980435 @default.
• W2118730804 hasConcept C2779489039 @default.
• W2118730804 hasConcept C2781276175 @default.
• W2118730804 hasConcept C2781414143 @default.
• W2118730804 hasConcept C3019249092 @default.
• W2118730804 hasConcept C501593827 @default.
• W2118730804 hasConcept C523546767 @default.
• W2118730804 hasConcept C54355233 @default.
• W2118730804 hasConcept C71924100 @default.
• W2118730804 hasConcept C86803240 @default.
• W2118730804 hasConcept C89423630 @default.
• W2118730804 hasConcept C98274493 @default.
• W2118730804 hasConceptScore W2118730804C176947019 @default.
• W2118730804 hasConceptScore W2118730804C185592680 @default.
• W2118730804 hasConceptScore W2118730804C26381139 @default.
• W2118730804 hasConceptScore W2118730804C2777052132 @default.
• W2118730804 hasConceptScore W2118730804C2778607973 @default.
• W2118730804 hasConceptScore W2118730804C2778980435 @default.
• W2118730804 hasConceptScore W2118730804C2779489039 @default.
• W2118730804 hasConceptScore W2118730804C2781276175 @default.

• next